Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Mesoblast Ltd ADR (MESO)

Mesoblast Ltd ADR (MESO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 908,173
  • Shares Outstanding, K 129,739
  • Annual Sales, $ 32,160 K
  • Annual Income, $ -77,940 K
  • 60-Month Beta 3.39
  • Price/Sales 147.19
  • Price/Cash Flow N/A
  • Price/Book 1.52
Trade MESO with:

Options Overview

Details
  • Implied Volatility 92.32%
  • Historical Volatility 39.11%
  • IV Percentile 6%
  • IV Rank 6.02%
  • IV High 285.16% on 08/11/20
  • IV Low 79.96% on 04/13/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 897
  • Volume Avg (30-Day) 760
  • Put/Call OI Ratio 0.63
  • Today's Open Interest 24,238
  • Open Int (30-Day) 23,494

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.16
  • Number of Estimates 2
  • High Estimate -0.15
  • Low Estimate -0.16
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +46.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.78 +9.73%
on 07/19/21
7.88 -5.58%
on 07/12/21
-0.37 (-4.74%)
since 07/02/21
3-Month
6.66 +11.63%
on 05/13/21
8.85 -15.93%
on 06/18/21
+0.19 (+2.62%)
since 05/04/21
52-Week
6.66 +11.63%
on 05/13/21
21.28 -65.04%
on 08/17/20
-8.01 (-51.84%)
since 08/04/20

Most Recent Stories

More News
Appendix 4C Quarterly Activity Report

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its pipeline of late-stage product candidates, and an activity...

MESO : 7.44 (+0.40%)
Ninety Day Survival Outcomes in COVID-19 ARDS Trial of Remestemcel-L Presented at ISCT Meeting on Advances in Cell & Gene Therapies for Lung Diseases

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, presented 90-day survival outcomes from the 222-patient randomized controlled trial of...

MESO : 7.44 (+0.40%)
Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today presented clinical outcomes from the randomized controlled trial of remestemcel-L...

MESO : 7.44 (+0.40%)
Mesoblast Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the strategy for bringing rexlemestrocel-L to patients in...

MESO : 7.44 (+0.40%)
Pain Relief Therapeutics Market 2021 Opportunity Assessment, Business Opportunities, Top Industry Players, Trend and Growth to 2027

ABT : 121.57 (-0.45%)
ACRX : 1.1500 (-4.17%)
ACOR : 3.75 (-3.10%)
AXSM : 49.35 (+0.35%)
BAYRY : 14.8000 (-1.00%)
BDRFF : 118.2500 (-1.21%)
BDSI : 3.75 (-3.85%)
BMY : 68.49 (-1.18%)
COLL : 24.94 (-1.23%)
DEPO : 7.30 (+1.67%)
DRRX : 1.3000 (-3.70%)
EGLT : 0.0315 (-63.37%)
LLY : 262.47 (+2.53%)
FLXN : 5.79 (-4.14%)
GLPG : 60.73 (-0.44%)
HRTX : 11.87 (-0.50%)
KMPH : 9.72 (-1.72%)
MRK : 75.48 (-1.22%)
MESO : 7.44 (+0.40%)
NKTR : 15.62 (-1.14%)
NVS : 91.59 (-1.21%)
ORXOY : 4.5350 (+1.91%)
PFE : 45.19 (-1.07%)
REGN : 580.95 (-0.95%)
VRX.TO : 30.80 (-3.33%)
Operational Highlights and Financial Results for the Period Ended March 31, 2021

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended March...

MESO : 7.44 (+0.40%)
Mesoblast Corporate Update and Financial Results Webcast

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to discuss operational highlights and financial results for...

MESO : 7.44 (+0.40%)
US Pain Relief Therapeutics Market Share 2021 : Growth Opportunities with Covid-19 Impact Analysis, Business Structure with Top Key Players Size, Development Plans and Challenges Forecast to 2027

The rising prevalence of chronic diseases such as a variety of cancers, osteoarthritis, stomach ulcer, chronic arthritis and diabetes are major key factor which drives the Global Pain Relief Therapeutics...

ABT : 121.57 (-0.45%)
ACRX : 1.1500 (-4.17%)
ACOR : 3.75 (-3.10%)
AXSM : 49.35 (+0.35%)
BAYRY : 14.8000 (-1.00%)
BDRFF : 118.2500 (-1.21%)
BDSI : 3.75 (-3.85%)
BMY : 68.49 (-1.18%)
COLL : 24.94 (-1.23%)
DEPO : 7.30 (+1.67%)
DRRX : 1.3000 (-3.70%)
EGLT : 0.0315 (-63.37%)
LLY : 262.47 (+2.53%)
FLXN : 5.79 (-4.14%)
GLPG : 60.73 (-0.44%)
HRTX : 11.87 (-0.50%)
KMPH : 9.72 (-1.72%)
MRK : 75.48 (-1.22%)
MESO : 7.44 (+0.40%)
NKTR : 15.62 (-1.14%)
NVS : 91.59 (-1.21%)
ORXOY : 4.5350 (+1.91%)
PFE : 45.19 (-1.07%)
REGN : 580.95 (-0.95%)
VRX.TO : 30.80 (-3.33%)
Improved Outcomes in Inflammatory Lung Disease With Remestemcel-L Published in Respiratory Research Journal

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the peer-reviewed journal Respiratory Research has published results...

MESO : 7.44 (+0.40%)
Strength Seen in Mesoblast Limited (MESO): Can Its 6.1% Jump Turn into More Strength?

Mesoblast Limited (MESO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down...

MESO : 7.44 (+0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's...

See More

Key Turning Points

3rd Resistance Point 7.74
2nd Resistance Point 7.66
1st Resistance Point 7.55
Last Price 7.44
1st Support Level 7.36
2nd Support Level 7.28
3rd Support Level 7.17

See More

52-Week High 21.28
Fibonacci 61.8% 15.70
Fibonacci 50% 13.97
Fibonacci 38.2% 12.25
Last Price 7.44
52-Week Low 6.66

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar